- gsearch

- gsearch

CDC Stacks Public Health Publications

Search Results

Morbidity and Mortality Weekly Report (MMWR) Morbidity and Mortality Weekly Report (MMWR)

Morbidity and Mortality Weekly Report (MMWR)

The Morbidity and Mortality Weekly Report (MMWR) series are CDC’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. The MMWR series includes the following publications: MMWR Weekly, MMWR Recommendations and Reports, CDC Surveillance Summaries and MMWR Supplements. These journals are freely available to the public as Diamond Open Access. For more on MMWR, visit https://www.cdc.gov/mmwr/index.html.

Narrow Results:
Volume
Series
Publication Year
Medical Subject
Personal Author
  • x
    Files, D. Clark (20)
Corporate Author
Place as Subject
Resource Type General
x Files, D. Clark
  • Characteristics of Adult Outpatients and Inpatients with COVID19  11 Academic Medical Centers United States MarchMay 2020
    Characteristics of Adult Outpatients and Inpatients with COVID-19 — 11 Academic Medical Centers, United States, March–May 2020
    :
    :
  • Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID19 in a Multistate Health Care Systems Network  United States MarchJune 2020
    Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020
    :
    :
  • Seroprevalence of SARSCoV2 Among Frontline Health Care Personnel in a Multistate Hospital Network  13 Academic Medical Centers AprilJune 2020
    Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network — 13 Academic Medical Centers, April–June 2020
    :
    :
  • Characteristics of Adult Outpatients and Inpatients with COVID19  11 Academic Medical Centers United States MarchMay 2020
    Characteristics of Adult Outpatients and Inpatients with COVID-19 — 11 Academic Medical Centers, United States, March–May 2020
    :
    :
  • Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID19 in a Multistate Health Care Systems Network  United States MarchJune 2020
    Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020
    :
    :
  • Seroprevalence of SARSCoV2 Among Frontline Health Care Personnel in a Multistate Hospital Network  13 Academic Medical Centers AprilJune 2020
    Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network — 13 Academic Medical Centers, April–June 2020
    :
    :
  • Community and Close Contact Exposures Associated with COVID19 Among Symptomatic Adults 18 Years in 11 Outpatient Health Care Facilities  United States July 2020
    Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020
    :
    :
  • Telework Before Illness Onset Among Symptomatic Adults Aged 18 Years With and Without COVID19 in 11 Outpatient Health Care Facilities  United States July 2020
    Telework Before Illness Onset Among Symptomatic Adults Aged ≥18 Years With and Without COVID-19 in 11 Outpatient Health Care Facilities — United States, July 2020
    :
    :
  • Decline in SARSCoV2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network  12 States AprilAugust 2020
    Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020
    :
    :
  • Effectiveness of PfizerBioNTech and Moderna Vaccines Against COVID19 Among Hospitalized Adults Aged 65 Years  United States JanuaryMarch 2021
    Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    :
    :
  • Comparative Effectiveness of Moderna PfizerBioNTech and Janssen Johnson  Johnson Vaccines in Preventing COVID19 Hospitalizations Among Adults Without Immunocompromising Conditions  United States MarchAugust 2021
    Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
    :
    :
  • Sustained Effectiveness of PfizerBioNTech and Moderna Vaccines Against COVID19 Associated Hospitalizations Among Adults  United States MarchJuly 2021
    Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
    :
    :
  • Effectiveness of PfizerBioNTech and Moderna Vaccines Against COVID19 Among Hospitalized Adults Aged 65 Years  United States JanuaryMarch 2021
    Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    :
    :
  • Sustained Effectiveness of PfizerBioNTech and Moderna Vaccines Against COVID19 Associated Hospitalizations Among Adults  United States MarchJuly 2021
    Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
    :
    :
  • Comparative Effectiveness of Moderna PfizerBioNTech and Janssen Johnson  Johnson Vaccines in Preventing COVID19 Hospitalizations Among Adults Without Immunocompromising Conditions  United States MarchAugust 2021
    Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
    :
    :
  • Effectiveness of MRNA Vaccination in Preventing COVID19associated Invasive Mechanical Ventilation and Death  United States March 2021January 2022
    Effectiveness of MRNA Vaccination in Preventing COVID-19–associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022
    :
    :
  • Effectiveness of a Third Dose of PfizerBioNTech and Moderna Vaccines in Preventing COVID19 Hospitalization Among Immunocompetent and Immunocompromised Adults  United States AugustDecember 2021
    Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
    :
    :
  • Effectiveness of mRNA Vaccination in Preventing COVID19Associated Invasive Mechanical Ventilation and Death  United States March 2021January 2022
    Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022
    :
    :
  • Effectiveness of Monovalent mRNA Vaccines Against COVID19Associated Hospitalization Among Immunocompetent Adults During BA1BA2 and BA4BA5 Predominant Periods of SARSCoV2 Omicron Variant in the United States  IVY Network 18 States December 26 2021August 31 2022
    Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022
    :
    :
  • Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID19Associated Hospitalization Among Immunocompetent Adults Aged 65 Years  IVY Network 18 States September 8November 30 2022
    Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022
    :
    :